- The FDA has approved Apellis Pharmaceuticals Inc's APLS Empaveli (pegcetacoplan) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).
- PNH is a rare blood disease that causes red blood cells to break apart because the surface of a person's blood cells is missing a protein that protects them from the body's immune system.
- The drug is approved for use in adults with PNH who are treatment naïve and patients switching from the C5 inhibitors Soliris (eculizumab) and Ultomiris (ravulizumab).
- The company says Empaveli is the first and only targeted C3 therapy for PNH.
- Price Action: APLS shares are up 10.7% at $49 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
